Pharmaceutical Technology Europe, Sep 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Sep 1, 2012
Special Feature
Strategies for High Containment
By Patricia Van Arnum
Experts share insight on facility design and operations for high-potency manufacturing.
Editor's Comment
European Commission Investigates Pay-to-Delay Deals
By Stephanie Sutton
Following an inquiry in 2009 that suggested the launch of various generic drugs was being delayed by anticompetitive business practices, the European Commission (EC) has been closely monitoring deals for potential breaches of the EU's antitrust rules.
Industry Insider
Regulatory Intervention in Paediatric Medicines
By Nathan Jessop
Regulators in both the EU and the US have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects?
Outsoucing Review
The Macro View
By Jim Miller
The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Ask the Expert
Tackling Tablet Sticking
Rob Blanchard and Clive Roberts discuss the issues surrounding tablet sticking.
Disposables Advisor
Pre-use Filter-Integrity Testing: To Test or Not To Test?
By Jerold Martin
There is no harmonized guidance on pre-use integrity testing of sterilizing filters, prompting discussion among users as to whether such testing is necessary.
News
News
By Stephanie Sutton
Big Pharma Placed in Malpractice Spotlight and other news from across the globe.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here